News

Filter

Current filters:

Chief medical officer

FDA lifts partial clinical hold for OncoMed’s vantictumab trials

FDA lifts partial clinical hold for OncoMed’s vantictumab trials

29-08-2014

US biotech firm OncoMed Pharmaceuticals saw its shares leap 9.9% to $21.58 on Thursday on news that the…

BiotechnologyChief medical officerOncologyOncoMed PharmaceuticalsResearchRevised trial protocolsRevised trial protocolsUnited StatesUSAvantictumab

COMPANY SPOTLIGHT

Menarini

Back to top